Edmund Bartlett, MD
Soft Tissue Sarcoma; Melanoma; Merkel Cell Carcinoma; Splenic Neoplasms
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Bartlett accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of Pennsylvania Medical School
General Surgery – Hospital of the University of Pennsylvania
Complex General Surgical Oncology – Memorial Sloan Kettering Cancer Center
The treatment of melanoma is changing at a remarkable rate. Recent trials have changed our surgical approach to people with disease that has spread to lymph nodes. The development of effective immunotherapies has revolutionized our ability to treat advanced disease. I work closely with my partners in medical and radiation oncology to determine the best care plan for people with melanoma. I am actively studying ways we can apply the lessons and progress we have made in melanoma to such rare cancers as soft tissue sarcoma and Merkel cell carcinoma.
For early-stage melanoma, I am interested in using sentinel lymph node biopsy. This special type of biopsy helps us tell how likely it is that the cancer will spread to other parts of the body. I also work to identify people who can avoid the procedure. For higher-risk melanoma, when the disease may have already spread to the lymph nodes, I am working to refine the best types of treatments — including surgery, radiation, and immune therapies — and which order to use them. I am a member of the Melanoma Disease Management Team. This wonderful resource allows care teams to discuss patients in a multidisciplinary approach. We are able to use our collective expertise to identify the best treatment for each individual.
I am also a member of the Sarcoma Disease Management Team. Soft tissue sarcoma is a rare cancer with approximately 80 subtypes. Each subtype behaves and responds to treatment differently. As such, people with soft tissue sarcoma need a care team with deep expertise, one that is dedicated to using a personalized approach for each patient. MSK has been a leader in applying new immune therapy strategies to sarcoma. I am interested in identifying sarcoma subtypes that may be effectively treated by immunotherapy.
I have a particular research interest in the development of clinical trials. My current efforts are focused on using immunotherapy in patients before it has been detected if the cancer will spread. One such trial currently enrolling patients uses immunotherapy treatments in people with sarcoma before surgery in the hopes it will decrease the chance of the cancer coming back. The trials we are developing and the studies we perform are motivated by our interest in providing new treatment options that will maximize chances for a cure and minimize treatment-related complications.
Although the research being done to advance our treatment of people with cancer is critically important, I am first and foremost a surgeon who interested in providing optimal care for my patients. I received dedicated training in the treatment of sarcoma as the Kristen Ann Carr Sarcoma Fellow at MSK and was awarded the Michael E. Burt Award for clinical excellence in 2018.
- Clinical Trials Investigated by Dr. Bartlett
- A Phase II Study of Pembrolizumab Immunotherapy plus Local Chemotherapy using Isolated Limb Infusion for Patients with Advanced Sarcoma in the Arm or Leg
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC. Ann Surg Oncol. 2016 Jan;23(1):250-6.
Current staging and prognostic factors in melanoma. Bartlett EK, Karakousis GC. Surg Oncol Clin N Am. 2015 Apr;24(2):215-27.
Outcomes after resection of leiomyosarcomas of the inferior vena cava: a pooled data analysis of 377 cases. Wachtel H, Gupta M, Bartlett EK, Jackson BM, Kelz RR, Karakousis GC, Fraker DL, Roses RE. Surg Oncol. 2015 Mar;24(1):21-7.
The rise in metastasectomy across cancer types over the past decade. Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Cancer. 2015 Mar 1;121(5):747-57.
Preoperative radiation for retroperitoneal sarcoma is not associated with increased early postoperative morbidity. Bartlett EK, Roses RE, Meise C, Fraker DL, Kelz RR, Karakousis GC. J Surg Oncol. 2014 May;109(6):606-11
Visit PubMed for a full listing of Dr. Bartlett’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Edmund Bartlett discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.